(Q34803014)

4 August 2017

1 reference

title

Pharmaco-economics of blood transfusion safety: review of the available evidence (English)

1 reference

4 August 2017

van Hulst M

1

1 reference

4 August 2017

de Wolf JT

2

1 reference

4 August 2017

Staginnus U

3

1 reference

4 August 2017

Ruitenberg EJ

4

1 reference

4 August 2017

Postma MJ

5

1 reference

4 August 2017

publication date

1 August 2002

1 reference

4 August 2017

1 reference

4 August 2017

volume

83

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

146-155

1 reference

Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Health economic guidelines--similarities, differences and some implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Human T-cell lymphotropic virus testing of blood donors in Norway: a cost-effect model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections. The HIV Blood Donor Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Hepatitis viruses and the safety of blood donations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Seroprevalence of known and putative hepatitis markers in United States blood donors with ALT levels at least 120 IU per L.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Including polymerase chain reaction in screening for hepatitis C virus RNA in blood donations is not cost-effective

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Screening for human T cell leukaemia/lymphoma virus among blood donors in Sweden: cost effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Cost-effectiveness of blood transfusion and white cell reduction in elective colorectal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Evidence-based recommendations for the use of WBC-reduced cellular blood components

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Interpretation of cost-effectiveness analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Assessing the benefits of transplant services

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Cost-effectiveness of lung transplantation in The Netherlands: a scenario analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Determinants of transfusion-associated bacterial contamination: results of the French BACTHEM Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Single-donor platelets reduce the risk of septic platelet transfusion reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1423-0410.2002.00198.X

10.1046/J.1423-0410.2002.00198.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference